Plain-English translation of NCT06630715 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking at how well a medication called upadacitinib works for people with two specific types of joint arthritis: psoriatic arthritis and rheumatoid arthritis. Researchers will follow your progress over 6 months with regular check-ups, blood tests, and imaging to see how well the medication controls your disease. The study also compares how the medication works in each type of arthritis to help doctors understand its benefits better.
While this medication is already used to treat arthritis, doctors want to better understand how well it works specifically for psoriatic arthritis and compare that to its effects in rheumatoid arthritis. This research will help guide treatment decisions and show how imaging can best track improvement over time.
You likely qualify if…
You likely don't qualify if…
You will begin taking the medication as part of your normal arthritis care, and researchers will track your progress through scheduled visits at approximately 1 month, 3 months, and 6 months after starting. At each visit, you'll have blood tests, imaging scans, and physical exams to measure inflammation and joint damage. You'll also complete questionnaires about your pain and function, including one at 2 weeks to capture early improvements. All information is gathered from routine clinical care and medical records.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Italy